What's New in the 2026 WADA Prohibited List The 2026 list updates, [2] approved by WADA's Executive Committee in September 2025, primarily provide clarifications and additions to existing categories
Cerebrolysin and Semax have extensive clinical safety data spanning decades
The convergence of evidence from animal models, human cohort studies, and mechanistic investigations strongly supports the conclusion that EED exposure creates heritable reproductive dysfunction through epigenetic mechanisms, fundamentally expanding our understanding of environmental health risks beyond individual exposure effects
Furthermore, clinical manifestations of withdrawal, such as dysphoria and irritability, mirror neurobiological adaptive mechanisms that involve greater stress sensitivity and hyperactivation of the hypothalamic-pituitary-adrenal axis, which could account for the increase in BDNF levels [38, 39]
Safety and Tolerability: Although both peptides have demonstrated generally manageable side effect profiles individually (with Retatrutide's GI effects being common), the safety of their combination is unknown
